Added to basket
Unapplied Changes
Sinclair Pharma has announced a treble milestone—the despatch of its one millionth syringe of Ellansé during the tenth anniversary celebrations of its unique bio-stimulating dermal filler at IMCAS.
Ellansé is now used to treat patients in 65 countries and to manage its burgeoning growth the company is in the process of setting up a new manufacturing facility in the Netherlands, currently housed within the University of Utrecht. This new dedicated site will allow for an increase in production capacity in anticipation of launching the product into China.
The company will be marking these milestones in the UK with a celebratory drinks reception on stand B8 at ACE—during which it will be holding a prize draw. Current Ellansé users will also have access to special anniversary marketing materials, including an updated 10th anniversary Beauty Book.
Publishing new papers
Thanks to the contribution of a number of international experts Sinclair Pharma has built a robust credibility for Ellansé in the medical aesthetics sector and scientific community. The company has invested heavily to build scientific knowledge and since 2011 there have been annual publications and studies published about the product.
Not ones to rest on their laurels however, Sinclair Phrama will be publishing three new papers in the first quarter of the year which will expand practitioners’ knowledge and understanding of Ellansé’s mode of action, longevity and safety—including a European study about longevity and safety; a Polycaprolactone (PCL) review; and a white paper on skin quality improvement.
